Mason A, Sallie R, Perrillo R, Rayner A, Xu L, Dohner D E, Dehner M, Naoumov N, Gelb L, Saha B, O'Grady J, Williams R
Section of Gastroenterology and Hepatology, Alton Ochsner Medical Institutions, New Orleans, LA 70121, USA.
Hepatology. 1996 Dec;24(6):1361-5. doi: 10.1002/hep.510240608.
Members of the herpes virus family and hepatitis B virus (HBV) have been implicated as etiologic agents in non-A, non-B (NANB) fulminant hepatic failure (FHF), but the frequency of infection with these agents has not been established using appropriate controls. To examine this issue, we studied 50 NANB FHF patients and 104 liver transplant recipients from North America and Europe. Hepatic DNA was analyzed by polymerase chain reaction (PCR) for evidence of Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus I (HSV I) and II (HSV II), varicella-zoster virus (VZV), and human herpes virus-6 (HHV-6) nucleic acid sequences. The prevalence of HBV was assessed in North American subjects only. HSV I, HSV II, VZV, and HHV-6 viral sequences were not observed in any samples. Three of 50 FHF (6%) and 14 of 104 control patients (13%) were positive for CMV DNA. Two of 50 FHF (4%) and 10 of 104 control patients (10%) had EBV DNA, and HBV DNA was observed in 3 of 10 North American FHF patients (30%) and 3 of 59 controls (5%) without serum markers for HBV infection. The finding of HBV DNA in the liver of seronegative controls from North America but not Europe suggests that occult hepatitis B sequences in patients with NANB FHF may simply reflect geographic differences. The majority of cryptogenic FHF cases cannot be attributed to infection with herpes viruses or HBV.
疱疹病毒家族成员和乙型肝炎病毒(HBV)被认为是非甲非乙型(NANB)暴发性肝衰竭(FHF)的病原体,但尚未通过适当对照确定这些病原体的感染频率。为研究此问题,我们对来自北美和欧洲的50例NANB FHF患者和104例肝移植受者进行了研究。通过聚合酶链反应(PCR)分析肝DNA,以寻找爱泼斯坦-巴尔病毒(EBV)、巨细胞病毒(CMV)、单纯疱疹病毒I型(HSV I)和II型(HSV II)、水痘-带状疱疹病毒(VZV)以及人类疱疹病毒6型(HHV-6)核酸序列的证据。仅在北美受试者中评估了HBV的流行情况。在任何样本中均未观察到HSV I、HSV II、VZV和HHV-6病毒序列。50例FHF患者中有3例(6%)和104例对照患者中有14例(13%)CMV DNA呈阳性。50例FHF患者中有2例(4%)和104例对照患者中有10例(10%)有EBV DNA,并且在10例北美FHF患者中有3例(30%)以及59例对照中有3例(5%)在无HBV感染血清标志物的情况下检测到HBV DNA。在北美而非欧洲的血清阴性对照肝脏中发现HBV DNA,这表明NANB FHF患者中隐匿性乙肝序列可能仅仅反映了地域差异。大多数原因不明的FHF病例不能归因于疱疹病毒或HBV感染。